In comparison to the cohort of HIV/HCV-coinfected patients receiving (Table 2, Fig. 3, Supplementary Table S1) IFN-free regimens, patients in the BOC-based triple therapy group (13 men, 4 women) were younger (37.2 ± 8.8 vs. 49.9 ± 7.6 years; P < 0.001), had less advanced liver disease (17.6% vs. 93.9% with F3/F4), and showed a better BL physical health (mean PCS values at BL: 53.9 ± 9.7 vs. 41.4 ± 9.7; P < 0.001) and less fatigue (FSS at BL: 26.8 ± 10.8 vs. 37.8 ± 14.0; P < 0.01) as compared to the IFN-free study population. Here, IFNA1 is linked to liver disorder.